More information about selecting biologics was investigated, such as difficult-to-treat psoriasis areas, short-term effectiveness, and long-term drug survival on IL-17 and IL-23 inhibitors in biologics-naïve patients or after adalimumab failure [6,7,8]. The gene discussed is IL17A; the disease is psoriasis.